Trial reportDrug and alcohol dependence2012
Modafinil for the treatment of methamphetamine dependence.
Trial report in Drug and alcohol dependence, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00520286 (Phase2, Double-blind, Placebo-controlled Trial of Modafinil for the Treatment of Methamphetamine Dependence), which is not on this map. Cited by 72 papers, 10 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase2, Double-blind, Placebo-controlled Trial of Modafinil for the Treatment of Methamphetamine Dependence
Who cites it
72 citing papers in PubMed, 10 syntheses or guidelines pooled it, 112 citations in OpenAlex.
- Evaluating Reduced Use and Abstinence as Outcomes in Pharmacotherapy Trials for Stimulant Use Disorder: A Meta-Analysis of 12 Randomized Controlled Trials.JAMA psychiatry · 2026Pooled it
- Translational medications development for methamphetamine use disorder: A systematic review of preclinical, human laboratory, and clinical research.Pharmacological reviews · 2026Pooled it
- Gender differences in the impact of psychological distress on methamphetamine use disorder outcomes and treatment effect.Addiction (Abingdon, England) · 2026Pooled it
- Efficacy and Safety of Modafinil for Treatment of Amphetamine-Type Stimulant Use Disorder: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials: Efficacité et innocuité du modafinil pour le traitement des troubles liés à l'usage de stimulants de type amphétamine : revue systématique et méta-analyse d'essais randomisés contrôlés par placebo.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2024Pooled it
- Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis.Psychopharmacology · 2020Pooled it
- Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review.CNS drugs · 2020Pooled it
- Methamphetamine-Related Disorders.Deutsches Arzteblatt international · 2017Guideline
- Efficacy and safety of psychostimulants for amphetamine and methamphetamine use disorders: a systematic review and meta-analysis.Systematic reviews · 2016Pooled it
- Efficacy of psychostimulant drugs for amphetamine abuse or dependence.The Cochrane database of systematic reviews · 2013Pooled it
- The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder.Journal of addiction medicineGuideline
- Cocaine craving and use during pharmacotherapy trials for cocaine use disorder: A multi-trajectory analysis.Drug and alcohol dependence · 2025Trial
- Trial
- A double blind, placebo controlled trial of modafinil for the treatment of cocaine dependence without co-morbid alcohol dependence.Drug and alcohol dependence · 2015Trial
- Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial.Drug and alcohol dependence · 2015Trial
- Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use.Addiction (Abingdon, England) · 2014Trial
- Event-level relationship between methamphetamine use significantly associated with non-adherence to pharmacologic trial medications in event-level analyses.Drug and alcohol dependence · 2014Trial
- Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder.Addiction (Abingdon, England) · 2014Trial
- Aripiprazole for the treatment of methamphetamine dependence: a randomized, double-blind, placebo-controlled trial.Addiction (Abingdon, England) · 2013Trial
- The role of polysubstance use in the development, maintenance, and treatment of stimulant use disorders.Pharmacological reviews · 2026Review
- Association Between Psychiatric Comorbidity and Retention in Substance Use Disorder Treatment: Results From Multi-Site Randomized Controlled Trials of Pharmacological and Behavioral Interventions.Journal of dual diagnosis · 2026Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 13 institutions in 1 country.
Funding
Abstract
aimModafinil was tested for efficacy in decreasing use in methamphetamine-dependent participants, compared to placebo.
methodsThis was a randomized, double-blind, placebo-controlled study, with 12 weeks of treatment and a 4-week follow-up. Eight outpatient substance abuse treatment clinics participated in the study. There were 210 treatment-seekers randomized, who all had a DSM-IV diagnosis of methamphetamine dependence; 68 participants to placebo, 72 to modafinil 200mg, and 70 to modafinil 400mg, taken once daily on awakening. Participants came to the clinic three times per week for assessments, urine drug screens, and group psychotherapy. The primary outcome measure was a methamphetamine non-use week, which required all the week's qualitative urine drug screens to be negative for methamphetamine.
resultsRegression analysis showed no significant difference between either modafinil group (200 or 400mg) or placebo in change in weekly percentage having a methamphetamine non-use week over the 12-week treatment period (p=0.53). Similarly, a number of secondary outcomes did not show significant effects of modafinil. However, an ad-hoc analysis of medication compliance, by urinalysis for modafinil and its metabolite, did find a significant difference in maximum duration of abstinence (23 days vs. 10 days, p=0.003), between those having the top quartile of compliance (>85% of urines were positive for modafinil, N=36), and the lower three quartiles of modafinil 200 and 400mg groups (N=106).
conclusionsAlthough these data suggest that modafinil, plus group behavioral therapy, was not effective for decreasing methamphetamine use, the study is probably inconclusive because of inadequate compliance with taking medication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.